retatrutide phase 3 triumph 🚨 JUST RELEASED TODAY!!!! NEW DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what is already one of the most interesting obesity drug retatrutide #obesity #osteoarthritis #clinicaltrials #medicine

However, in 2024 Eli Lilly spent $2.5 billion on share repurchases and increased its quarterly dividend by 15%

While some reviews mention delays, the guarantee provides risk-free trial potential

Finally, similar to GLP-1 RAs, the medication should not be used in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [31, 43]

The NHS website provides information on weight management services, and NICE's guideline on obesity (CG189, or its current replacement) and patient decision aids can help you understand your options

Rat G1 was the same as the construct used in the GIPR structure determination

In July, the company closed its acquisition of European digital healthcare provider Zava